Perspective Therapeutics (CATX) vs iRadimed (IRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
iRadimed (IRMD) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 16.0% versus a loss of 31.1%. Over five years, IRMD leads with a +138.5% price change compared with -57.1% for CATX. iRadimed is the larger company by market cap ($1.12 billion vs $303.6 million), about 3.7 times the size.
iRadimed pays a dividend yielding 0.88%, while Perspective Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | IRMD |
|---|---|---|
| Share price | $2.66 | $87.45 |
| Market cap | $303.64M | $1.12B |
| 1-day change | -1.85% | +1.83% |
| YTD return | -3.27% | -10.10% |
| 1-year return | -31.09% | +15.95% |
| 5-year return | -57.10% | +138.48% |
| P/E ratio (TTM) | — | 48.85 |
| Forward P/E | — | 35.65 |
| EPS (TTM) | $-1.33 | $1.79 |
| Dividend yield | 0.00% | 0.88% |
| Annual dividend | $0.00 | $0.77 |
| Revenue (latest FY) | — | $83.81M |
| Revenue growth (YoY) | — | +14.43% |
| Net income (latest FY) | — | $22.48M |
| Gross margin | — | 76.75% |
| Operating margin | — | 31.20% |
| Net margin | — | 26.82% |
| 52-week high | $6.16 | $107.90 |
| 52-week low | $1.96 | $71.34 |
| Distance from 52-week high | -56.82% | -18.95% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +362.03% | +34.93% |
| Average volume | 1.64M | 125.52K |
| Shares outstanding | 114.15M | 12.79M |
| Employees | 163 | 166 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- iRadimed is about 3.7 times larger than Perspective Therapeutics by market value ($1.12B vs $303.64M).
- IRMD has outperformed CATX by 47.0 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About iRadimed
IRMD stock →IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
Health Care · Medical/Dental Instruments · 166 employees
CATX vs IRMD FAQ
Which is bigger, Perspective Therapeutics or iRadimed?
iRadimed (IRMD) is larger, with a market capitalization of $1.12B compared with $303.64M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or IRMD?
IRMD returned +15.95% over the past 12 months, compared with -31.09% for CATX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Perspective Therapeutics or iRadimed?
iRadimed pays a dividend yielding 0.88%, while Perspective Therapeutics does not currently pay a regular dividend.
Are Perspective Therapeutics and iRadimed in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Perspective Therapeutics and Medical/Dental Instruments for iRadimed.